
Our Mission
The Yale University Open Data Access (YODA) Project’s mission is to advocate for the responsible sharing of clinical research data, open science, and research transparency. The Project is committed to supporting research focused on improving the health of patients and informing science and public health. The YODA Project can only improve with your feedback. Please share your comments and ideas.
Our Model
The YODA Project seeks mutually beneficial partnerships with Data Partners, promoting independence, responsible conduct of research, good stewardship of data, and the generation of knowledge in the best interest of society. To participate, each Data Partner must transfer full jurisdiction over data access to the YODA Project.
Request Data
Are you ready to request data? To date, 449 trials have been identified as available. The YODA Project and Data Partners continue to identify and add more.
Featured Articles
Articles making use of data shared through the YODA Project. Scroll through featured articles below or learn more about approved data requests.
*104 publications from 88 research projects.
-
Trajectory of fecal lactoferrin for predicting prognosis in ulcerative colitis
Rirong Chen, Li Li, Yizhe Tie, Minhu Chen, Shenghong Zhang, Trajectory of fecal lactoferrin for predicting prognosis in ulcerative colitis, Precision Clinical Medicine, Volume 6, Issue 3, September 2023, pbad022, https://doi.org/10.1093/pcmedi/pbad022
-
Association between concomitant proton pump inhibitor use
and survival of patients with metastatic prostate cancer
receiving abiraterone acetate: a post-hoc analysis of pooled
data from three randomized controlled trialsFukuokaya W, Mori K, Yanagisawa T, Akazawa K, Shimomura T, Kimura T. Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials. Prostate Cancer Prostatic Dis. 2023 Jul 18. doi: 10.1038/s41391-023-00695-x. Epub ahead of print. PMID: 37464102.
-
Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index
Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index. Inflamm Bowel Dis. 2023 Apr 28:izad074. doi: 10.1093/ibd/izad074. Epub ahead of print. PMID: 37116893.
-
Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders
Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders. Clin Gastroenterol Hepatol. 2023 Jun 29:S1542-3565(23)00496-2. doi: 10.1016/j.cgh.2023.06.011. Epub ahead of print. PMID: 37391059.
-
Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial
Doi Y, Hamano T, Yamaguchi S, Sakaguchi Y, Kaimori JY, Isaka Y. Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial. Diabetes Obes Metab. 2023 Jun 29. doi: 10.1111/dom.15191. Epub ahead of print. PMID: 37385955.
-
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care. 2022 Apr 1;45(4):965-974. doi: 10.2337/dc21-1765. PMID: 35120199; PMCID: PMC9016734.
-
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease
d’Angremont E, Begemann MJH, van Laar T, Sommer IEC. Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis. JAMA Neurol. Published online June 26, 2023. doi:10.1001/jamaneurol.2023.1835
-
Fecal lactoferrin early predicts long-term outcomes in ulcerative colitis: A post-hoc analysis of the UNIFI and PURSUIT trials
Chen R, Tie Y, Zhang X, Li L, Chen M, Zhang S. Fecal lactoferrin early predicts long-term outcomes in ulcerative colitis: A post-hoc analysis of the UNIFI and PURSUIT trials. United European Gastroenterol J. 2023 Jun 23. doi: 10.1002/ueg2.12431. Epub ahead of print. PMID: 37350349.
-
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis
Hock RS, Feeney A, Iovieno N, et al. Rapidity of symptom improvement with intranasal esketamine for major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2023;84(1):21r14086.
-
Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients with Diabetes Mellitus: New Insights from CANVAS
Borisov AN, Kutz A, Christ ER, Heim MH, Ebrahimi F. Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients with Diabetes Mellitus: New Insights from CANVAS. J Clin Endocrinol Metab. 2023 May 7:dgad249. doi: 10.1210/clinem/dgad249. Epub ahead of print. PMID: 37149821.
-
Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study
Wong, E.C.L., Merat, S., Monaco, C. et al. Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study. Dig Dis Sci 68, 2635–2646 (2023). https://doi.org/10.1007/s10620-023-07956-8
-
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, Rathkopf DE, Saad F, Ryan CJ, Small EJ, Kelly WK. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Apr 11:JCO2202661. doi: 10.1200/JCO.22.02661. Epub ahead of print. PMID: 37040594.
-
Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials.
Burschinski A, Schneider-Thoma J, Chiocchia V, Schestag K, Wang D, Siafis S, Bighelli I, Wu H, Hansen WP, Priller J, Davis JM, Salanti G, Leucht S. Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials. World Psychiatry. 2023 Feb;22(1):116-128. doi: 10.1002/wps.21036. PMID: 36640396; PMCID: PMC9840505.
-
Guiding safer risperidone prescribing in Alzheimer’s disease with therapeutic drug monitoring
Roughley, M, Mena, C, Howard, R, Reeves, S, Bertrand, J. Guiding safer risperidone prescribing in Alzheimer’s disease with therapeutic drug monitoring. Br J Clin Pharmacol. 2023; 1- 6. doi:10.1111/bcp.15692
-
External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning
Loiseau, N., Trichelair, P., He, M. et al. External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning. BMC Med Res Methodol 22, 335 (2022). https://doi.org/10.1186/s12874-022-01799-z
-
Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: a systematic review with individual patient data network meta-analysis
Veroniki AA, Ashoor HM, Rios P, et al Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: a systematic review with individual patient data network meta-analysis BMJ Open 2022;12:e053012. doi: 10.1136/bmjopen-2021-053012
-
Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS
Hopkins, S.C., Ogirala, A., Zeni, C. et al. Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS. Clin Drug Investig 42, 1113–1121 (2022). https://doi.org/10.1007/s40261-022-01218-7
-
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial
S. Roy, Y. Sun, S.C. Morgan et al., Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial, Eur Urol (2023), https://doi.org/10.1016/j. eururo.2023.02.017
-
Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis
Brandt, L., et al. (2023). “Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis.” The Lancet Psychiatry 10(3): 184-196.
-
Data-sharing and re-analysis for main studies assessed by the European Medicines Agency—a cross-sectional study on European Public Assessment Reports
Siebert M, Gaba J, Renault A, Laviolle B, Locher C, Moher D, Naudet F. Data-sharing and re-analysis for main studies assessed by the European Medicines Agency-a cross-sectional study on European Public Assessment Reports. BMC Med. 2022 May 20;20(1):177. doi: 10.1186/s12916-022-02377-2. PMID: 35590360; PMCID: PMC9119701.
-
Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease: An ACCENT-II Post Hoc Analysis
Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease: An ACCENT-II Post Hoc Analysis. Am J Gastroenterol. 2021 May 1;116(5):1007-1014. doi: 10.14309/ajg.0000000000001111. PMID: 33929379; PMCID: PMC8095681.
-
Higher post-induction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn’s disease: an ACCENT-II post-hoc analysis
Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease: An ACCENT-II Post Hoc Analysis. Am J Gastroenterol. 2021 May 1;116(5):1007-1014. doi: 10.14309/ajg.0000000000001111. PMID: 33929379; PMCID: PMC8095681.
-
A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn’s Disease
Dulai PS, Jairath V, Narula N, Wong E, Kochhar GS, Colombel JF, Sandborn WJ. A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn’s Disease. Am J Gastroenterol. 2021 Aug 1;116(8):1709-1719. doi: 10.14309/ajg.0000000000001263. PMID: 34587127; PMCID: PMC8481677.
-
Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis
Gouraud H, Wallach JD, Boussageon R, et al Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis
BMJ Medicine 2022;1:e000154. doi: 10.1136/bmjmed-2022-000154
-
Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis
McCutcheon RA, Pillinger T, Efthimiou O, Maslej M, Mulsant BH, Young AH, Cipriani A, Howes OD. Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis. World Psychiatry. 2022 Jun;21(2):287-294. doi: 10.1002/wps.20977. PMID: 35524614; PMCID: PMC9077611.
-
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis
Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Predictors of Placebo Induction Response and Remission in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Aug 24:S1542-3565(22)00811-4. doi: 10.1016/j.cgh.2022.08.015. Epub ahead of print. PMID: 36029969.
-
Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis
Kerschbaumer A, Rivai ZI, Smolen JS, et al Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. Annals of the Rheumatic Diseases Published Online First: 20 June 2022. doi: 10.1136/annrheumdis-2021-221807
-
The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data
Zou X, Huang Q, Luo Y, Ren Q, Han X, Zhou X, Ji L. The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data. Diabetologia. 2022 Jul 8. doi: 10.1007/s00125-022-05748-9. Epub ahead of print. PMID: 35802168.
-
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease
Narula, Neeraj MD, MPH, FRCPC1; Wong, Emily C.L. BHSc1; Dulai, Parambir S. MD2; Marshall, John K. MD, MSc, FRCPC1; Jairath, Vipul MD, PhD3; Reinisch, Walter MD, PhD4 Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease, The American Journal of Gastroenterology: April 15, 2022 – Volume – Issue – 10.14309/ajg.0000000000001795 doi: 10.14309/ajg.0000000000001795
-
Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials.
Agrawal, Manasi & Petralia, Francesca & Tepler, Adam & Durbin, Laura & Reinisch, Walter & Colombel, Jean-Frederic & Shah, Shailja. (2022). Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials. Inflammatory Bowel Diseases. 10.1093/ibd/izac067.
-
Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes
Mishriky BM, Cummings DM, Powell JR. Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes. Prim Care Diabetes. 2022 Apr 5:S1751-9918(22)00073-0. doi: 10.1016/j.pcd.2022.03.012. Epub ahead of print. PMID: 35396200.
-
Three-Month FVC Change: A Trial Endpoint for IPF Based on Individual Participant Data Meta-Analysis
Khan FA, Stewart I, Moss S, Fabbri L, Robinson KA, Johnson SR, Jenkins RG. Three-Month FVC Change: A Trial Endpoint for IPF Based on Individual Participant Data Meta-Analysis. Am J Respir Crit Care Med. 2022 Jan 12. doi: 10.1164/rccm.202109-2091OC. Epub ahead of print. PMID: 35020580.
-
Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study
Kearns B, Stevenson MD, Triantafyllopoulos K, Manca A. Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study. BMC Med Res Methodol. 2021 Nov 27;21(1):263. doi: 10.1186/s12874-021-01460-1. PMID: 34837957; PMCID: PMC8627632.
-
Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn’s Disease
Narula N, Wong ECL, Colombel JF, Sandborn WJ, Ferrante M, Marshall JK, Reinisch W, Dulai PS. Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn’s Disease. J Crohns Colitis. 2021 Oct 19:jjab183. doi: 10.1093/ecco-jcc/jjab183. Epub ahead of print. PMID: 34664635.
-
Categorizing Endoscopic Severity of Crohn’s Disease Using the Modified Multiplier SES-CD (MM-SES-CD)
Narula N, Pray C, Wong ECL, Colombel JF, Marshall JK, Daperno M, Reinisch W, Dulai PS. Categorizing Endoscopic Severity of Crohn’s Disease Using the Modified Multiplier SES-CD (MM-SES-CD). J Crohns Colitis. 2022 Feb 3:jjac018. doi: 10.1093/ecco-jcc/jjac018. Epub ahead of print. PMID: 35134140.
-
Explainable AI enables clinical trial patient selection to retrospectively improve treatment effects in schizophrenia
Mellem MS, Kollada M, Tiller J, Lauritzen T. Explainable AI enables clinical trial patient selection to retrospectively improve treatment effects in schizophrenia. BMC Med Inform Decis Mak. 2021 May 20;21(1):162. doi: 10.1186/s12911-021-01510-0. PMID: 34016112; PMCID: PMC8135147.
-
Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials
Carretero-González A, Lora D, Manneh R, Lorente D, Castellano D, de Velasco G. Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials. Clin Transl Oncol. 2020 Nov;22(11):2126-2129. doi: 10.1007/s12094-020-02334-6. Epub 2020 Mar 20. PMID: 32198642.
-
Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis
Wang R, Dasgupta A, Ward MM. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis. JAMA Netw Open. 2022;5(3):e222312. doi:10.1001/jamanetworkopen.2022.2312
-
Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA
Wang J, Arroyo-Suarez R, Dasari S, Sekaran K, Tse W. Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA. Leuk Lymphoma. 2022 Feb 10:1-9. doi: 10.1080/10428194.2022.2038376. Epub ahead of print. PMID: 35142582.
-
Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease
Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease. Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16805. Epub ahead of print. PMID: 35166396.
-
Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis
Brandt L, Schneider-Thoma J, Siafis S, Efthimiou O, Bermpohl F, Loncar L, Neumann K, Hasan A, Heinz A, Leucht S, Gutwinski S. Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis. Lancet Psychiatry. 2022 Mar;9(3):232-242. doi: 10.1016/S2215-0366(22)00014-1. PMID: 35183280.
-
Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials
Sim R, Chong CW, Loganadan NK, et al. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials. Diabet Med. 2021 Dec 28:e14780. doi: 10.1111/dme.14780. Epub ahead of print. PMID: 34962662.
-
Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn’s Disease: A Pooled Analysis of 6 Trials
Beelen EMJ, Nieboer D, Arkenbosch JHC, et al. Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn’s Disease: A Pooled Analysis of 6 Trials. Clin Gastroenterol Hepatol. 2021 Oct 20:S1542-3565(21)01134-4. doi: 10.1016/j.cgh.2021.10.021. Epub ahead of print. PMID: 34687970.
-
Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials
Ben-Horin S, Novack L, Mao R, et al. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. Gastroenterology. 2022 Feb;162(2):482-494. doi: 10.1053/j.gastro.2021.10.037. Epub 2021 Oct 29. PMID: 34757139.
-
Meta-analysis of Total Effect Decomposition in the Presence of Multiple Mediators: The Example of Schizophrenia Treatment
Zhu Y, Centorrino F, Jackson JW, Fitzmaurice GM, Valeri L. Epidemiology. 2021 Jan;32(1):120-130. doi: 10.1097/EDE.0000000000001269. PMID: 33181564.
-
Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis
Narula N, Wong ECL, Marshall JK, Colombel JF, Dulai PS, Reinisch W. Clin Gastroenterol Hepatol. 2021 Jul 28:S1542-3565(21)00820-X. doi: 10.1016/j.cgh.2021.07.038. Epub ahead of print. PMID: 34329776.
-
Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer
Lorente D, Llacer C, Lozano R, et al. European Urology. 2021. doi: https://doi.org/10.1016/j.eururo.2021.07.014
-
Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data
Schoretsanitis G, Kane JM, Correll CU, Rubio JM. Schizophrenia Bulletin. 2021, sbab091. https://doi.org/10.1093/schbul/sbab091
-
Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis
Hieronymus F, Kølbæk P, Correll CU, Østergaard SD. npj Schizophrenia. 2021;7(1):41.
-
Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports
Hodkinson A, Heneghan C, Mahtani KR, Kontopantelis E, Panagioti M. BMC Med. 2021 Aug 25;19(1):195. doi: 10.1186/s12916-021-02062-w. PMID: 34429113; PMCID: PMC8386072.
-
Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials
Pan J, Wang J, Wei Y, Zhang T, Zhang S, Ye D, Zhu Y. Cancer Med. 2021 Aug 20. doi: 10.1002/cam4.4205. Epub ahead of print. PMID: 34414685.
-
The impact of ustekinumab on extraintestinal manifestations of Crohn’s disease: A post hoc analysis of the UNITI studies
Narula N, Aruljothy A, Wong ECL, Homenauth R, Alshahrani AA, Marshall JK, Reinisch W. United European Gastroenterol J. 2021 Jun;9(5):581-589. doi: 10.1002/ueg2.12094. Epub 2021 Jun 2. PMID: 34077627; PMCID: PMC8259251.
-
Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis
Wang L, Paller C, Hong H, Rosman L, De Felice A, Brawley O, Alexander GC. J Natl Cancer Inst. 2021 Apr 8:djab071. doi: 10.1093/jnci/djab071. Epub ahead of print. PMID: 33830214.
-
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis
Ternov KK, Nolsøe AB, Bratt O, Fode M, Lindberg H, Kistorp C, Palapattu G, Klausen TW, Sønksen J, Østergren PB. Prostate Cancer Prostatic Dis. 2021 Apr 5. doi: 10.1038/s41391-021-00359-8. Epub ahead of print. PMID: 33820951.
-
Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a post hoc analysis of phase 3 clinical trials
Wang J, Park C, Arroyo-Suarez R. Leuk Lymphoma. 2021 Apr 9:1-8. doi: 10.1080/10428194.2021.1910687. Epub ahead of print. PMID: 33836624.
-
Comparative Efficacy and Rapidity of Action for Infliximab vs. Ustekinumab in Biologic Naive Crohn’s Disease
Narula N, Wong ECL, Dulai P, Sengupta NK, Marshall JK, Colombel JF, Reinisch W. Clin Gastroenterol Hepatol. 2021 Apr 7. doi: https://doi.org/10.1016/j.cgh.2021.04.006. Epub ahead of print.
-
Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD)
Narula N, Wong ECL, Colombel JF, Sandborn WJ, Marshall JK, Daperno M, Reinisch W, Dulai P. Gut. 2021 Mar 25:gutjnl-2020-323799. doi: 10.1136/gutjnl-2020-323799. Epub ahead of print. PMID: 33766910.
-
Outcomes of Passable and Non-Passable Strictures in Clinical Trials of Crohn’s Disease: A Post-hoc Analysis
Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. J Crohns Colitis. 2021 Mar 6:jjab045. doi: 10.1093/ecco-jcc/jjab045. Epub ahead of print. PMID: 33693522.
-
OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies
Fraenkel L, Wei Z, Ramsey C, Wiedmeyer C, Michaud K, Neogi T, Nowell WB, Venkatachalam S, Broniatowski DA. PLoS One. 2021 Jan 29;16(1):e0245598. doi: 10.1371/journal.pone.0245598. PMID: 33513209.
-
Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis
Mishriky BM, Okunrintemi V, Jain S, Sewell KA, Powell JR, Cummings DM. Diabetes Metab. 2020 May 18:S1262-3636(20)30076-8. doi: 10.1016/j.diabet.2020.05.002. Epub ahead of print. PMID: 32439471.
-
Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease
Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Am. J. Gastroenterol. 2020 December 18. Publish Ahead of Print.
-
No relationship between bone mineral density and syndesmophyte formation at the same level in the lumbar spine of patients with radiographic axial Spondyloarthritis
Marques ML, Ramiro S, Machado PM, van der Heijde D, van Gaalen FA. RMD Open. 2020 Dec;6(3):e001391. doi: 10.1136/rmdopen-2020-001391. PMID: 33310864.
-
The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies
Lu TX, Dapas M, Lin E, Peters T, Sakuraba A. Gut. 2020 Dec 17:gutjnl-2020-321609. doi: 10.1136/gutjnl-2020-321609. Epub ahead of print. PMID: 33334900.
-
Consistency checks to improve measurement with the Personal and Social Performance Scale (PSP)
Rabinowitz J, Opler M, Rabinowitz AA, Negash S, Anderson A, Fu DJ, Williamson D, Kott A, Davis LL, Schooler NR. Schizophr Res. 2020 Nov 25:S0920-9964(20)30580-6. doi: 10.1016/j.schres.2020.11.040. Epub ahead of print. PMID: 33248884.<
-
Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial
Wong ECL, Marshall JK, Reinisch W, Narula N. Inflamm Bowel Dis. 2020 Aug 19; izaa214. doi: 10.1093/ibd/izaa214. Online ahead of print.
-
Identifying frailty in trials: an analysis of individual participant data from trials of novel pharmacological interventions
Hanlon P, Butterly E, Lewsey J, Siebert S, Mair FS, McAllister DA. BMC Med. 2020 Oct 22;18(1):309. doi: 10.1186/s12916-020-01752-1. PMID: 33087107; PMCID: PMC7579922.
-
Week 6 Calprotectin Best Predicts Likelihood of Long-Term Endoscopic Healing in Crohn’s Disease: A Post-Hoc Analysis of the UNITI/IM-UNITI Trials
Narula N, Wong ECL, Dulai PS, Marshall JK, Colombel JF, Reinisch W. J Crohns Colitis. 2020 Sep 15:jjaa189. doi: 10.1093/ecco-jcc/jjaa189. Epub ahead of print. PMID: 32931556.
-
Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients
Ferreira RJO, Welsing PMJ, Jacobs JWG, Gossec L, Ndosi M, Machado PM, van der Heijde D, Da Silva JAP. Ann Rheum Dis. 2020 Oct 6. doi: 10.1136/annrheumdis-2020-217171. Epub ahead of print.
-
Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis
Rubio JM, Schoretsanitis G, John M, Tiihonen J, Taipale H, Guinart D, Malhotra AK, Correll CU, Kane JM. Lancet Psychiatry. 2020;7(9):749-761. doi:10.1016/S2215-0366(20)30264-9
-
Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial
Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. Am J Gastroenterol. 2020;115(8):1236-1245. doi:10.14309/ajg.0000000000000617
-
Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn’s Disease: A Systematic Review and Pooled Meta-analysis
Faleck DM, Shmidt E, Huang R, Katta LG, Narula N, Pinotti R, Suarez-Farinas M, Colombel JF. Clin Gastroenterol Hepatol. [Epub ahead of print, 2020 Jun 19]. 2020;S1542-3565(20)30847-8. doi:10.1016/j.cgh.2020.06.036
-
Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis
Hanlon P, Hannigan L, Rodriguez-Perez J, Fischbacher C, Welton NJ, Dias S, Mair FS, Guthrie B, Wild S, McAllister DA. BMC Med. 2019 Nov 12;17(1):201. doi: 10.1186/s12916-019-1427-1.
-
Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials
Cheng D, Cushing KC, Cai T, Ananthakrishnan AN. Clin Gastroenterol Hepatol. 2020 May 1;pii: S1542-3565(20)30615-7. doi: 10.1016/j.cgh.2020.04.070. [Epub ahead of print]
-
Bayesian Meta-Analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs
Spertus J, Horvitz-Lennon M, Normand S. Med Decis Making. 2019 Aug 2:272989X19856884. [Epub ahead of print] doi: 10.1177/0272989X19856884
-
Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials
Christian KE, Russman KM, Rajan DP, Barr EA, Cross RK. Inflamm Bowel Dis. 2019 Jul 2. pii: izz133. doi: 10.1093/ibd/izz133. [Epub ahead of print]
-
Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis
Schneider-Thoma J, Efthimiou O, Bighelli I, Dörries C, Huhn M, Krause M, Reichelt L, Röder H, Furukawa TA, Davis JM, Leucht S. Lancet Psychiatry. 2019 July. 0(0). doi:10.1016/S2215-0366(19)30223-8.
-
Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials
Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V. Clin Gastroenterol Hepatol. 2019 May; pii:S1542-3565(19)30529-4. doi: 10.1016/j.cgh.2019.05.019. [Epub ahead of print]
-
Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease
Waljee AK, Wallace BI, Cohen-Mekelburg S, Liu Y, Liu B, Sauder K, Stidham RW, Zhu J, Higgins PDR. JAMA Netw Open 2019 May;2(5):e193721. doi: 10.1001/jamanetworkopen.2019.3721.
-
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302
Teply BA, Qiu F, Antonarakis ES, Carducci MA, Denmeade SR. Prostate. 2019 Jun;79(8):929-933. doi: 10.1002/pros.23798.
-
Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
Mbuagbaw L, Guglielmetti L, Hewison C, Bakare N, Bastard M, Caumes E, Fréchet-Jachym M, Robert J, Veziris N, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Schünemann HJ, Lienhardt C. Emerg Infect Dis. 2019 May;25(5):936-943. doi: 10.3201/eid2505.181823.
-
External Validation of a Thiopurine Monitoring Algorithm on the SONIC Clinical Trial Dataset
Waljee AK, Sauder K, Zhang Y, Zhu J, Higgins PDR. Clin Gastroenterol Hepatol. 2018 Mar;16(3):449-451. doi: 10.1016/j.cgh.2017.08.021.
-
A Standardisation Approach to Compare Treatment Safety and Effectiveness Outcomes between Clinical Trials and Real World Populations in Psoriasis
Yiu ZZN, Mason KJ, Barker JNWN, Hampton PJ, McElhone K, Smith CH, Warren RB, Griffiths CEM, Lunt M, Burden AD; BADBIR Study Group. Br J Dermatol. [Epub ahead of print 1 Mar 2019]. doi: 10.1111/bjd.17849.
-
Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study
Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P. Eur Urol Oncol. 2019. doi: 10.1016/j.
euo.2019.01.009 -
Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low vs. high risk of radiographic progression: An analysis of COU-AA-302
Martin LJ, Alibhai SMH, Komisarenko M, Timilshina N, Finelli A. Can Urol Assoc J. [Epub ahead of print 5 Nov 2018]. doi: 10.5489/cuaj.5586.
-
Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs
Kumagai F, Suzuki T, Fleischhacker WW, Yasui-Furukori N, Mimura M, Uchida H. J Clin Psychiatry. 2018 Dec 4;80(1). pii: 18m12144. doi: 10.4088/JCP.18m12144.
-
Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs
Kubo K, Fleischhacker WW, Suzuki T, Yasui-Furukori N, Mimura M, Uchida H. Acta Psychiatr Scand. [Epub ahead of print 9 Sep 2018]. doi: 10.1111/acps.12960.
-
Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis — a Systematic Review and Meta-Analysis
Narula N, Alshahrani AA, Yuan Y, Reinisch W, Colombel JF. Clin Gastroenterol Hepatol. [Epub ahead of print 15 Jun 2018] doi: 10.1016/j.cgh.2018.06.015.
-
Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials
Schneider-Thoma J, Efthimiou O, Huhn M, Krause M, Reichelt L, Röder H, Davis JM, Salanti G, Leucht S. Lancet Psychiatry. 2018;5(8):653-663. doi: 10.1016/S2215-0366.
-
The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data
Wilcox MA, Savitz AJ, Addington AM, Gray GS, Guinan EC, Jackson JW, Lehner T, Normand SL, Ranu H, Senthil G, Spertus J, Valeri L, Ross JS. NPJ Schizophr. 2018;4(1):14. doi: 10.1038/s41537-018-0055-7.
-
Risk of weight gain for specific antipsychotic drugs: a meta-analysis
Spertus J, Horvitz-Lennon M, Abing H, Normand S. NPJ Schizophr. [Epub ahead of print 27 June 2018] doi: 10.1038/s41537-018-0053-9
-
The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning: a causal mediation analysis approach
Zou X, Zhu Y, Jackson JW, Bellavia A, Fitzmaurice GM, Centorrino F, Valeri L. NPJ Schizophr. [Epub ahead of print 27 June 2018] doi: 10.1038/s41537-018-0054-8
-
Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials
Singh S, Proudfoot J, Xu R, Sandborn WJ. Inflamm Bowel Dis. [Epub ahead of print 18 May 2018] doi: 10.1093/ibd/izy135
-
Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials
Singh S, Proudfoot J, Xu R, Sandborn WJ. Am J Gastroenterol. 2018;113(6):883-889. doi: 10.1038/s41395-018-0104-x
-
No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials
Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. Am J Gastroenterol. [Epub ahead of print 21 June 2018] doi: 10.1038/s41395-018-0144-2
-
Review of Available Evidence on the Use of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis: Data Analysis Report
Mbuagbaw L. Appendix in A 2016 review of available evidence on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Geneva; 2017. WHO reference number: WHO/HTM/TB/2017.01
-
Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis
Wang R, Dasgupta A, Ward MM. J Rheumatol. [Epub ahead of print 15 January 2018] doi: 10.3899/jrheum.170224
-
Feasibility, Process, and Outcomes of Cardiovascular Clinical Trial Data Sharing: A Reproduction Analysis of the SMART-AF Trial
Gay HC, Baldridge AS, Huffman MD. JAMA Cardiology. [Epub ahead of print 18 October 2017] doi: 10.1001/jamacardio.2017.3808
-
Certolizumab Pegol and Secukinumab for Treating Active Psoriatic Arthritis Following Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Systematic Review and Economic Evaluation
Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, Walton M, Harden M, Ho P, Woolacott N, Bojke L. Health Technology Assessment. 2017;21(56).
-
Effectiveness and Harms of Recombinant Human Bone Morphogenetic Protein-2 in Spine Fusion: A Systematic Review and Meta-analysis
Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, Helfand M. Ann Intern Med. 2013;158:890-902.
-
5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI)
Mospan GA, Wargo KA. J Am Board Fam Med. 2016;29:654-662.
-
Meta-Analysis of the Impact of Patient Characteristics on Estimates of Effectiveness and Harms of Recombinant Human Bone Morphogenetic Protein-2 in Lumbar Spinal Fusion
Laurie AL, Chen Y, Chou R, Fu R. Spine. 2016;41:E1115-1123.
-
What Is the Clinical Relevance of Radiographic Nonunion After Single-Level Lumbar Interbody Arthrodesis in Degenerative Disc Disease?: A Meta-Analysis of the YODA Project Database
Noshchenko A, Lindley EM, Burger EL, Cain CM, Patel, VV. Spine. 2016;41:9-17.
-
Safety and Effectiveness of Recombinant Human Bone Morphogenetic Protein-2 for Spinal Fusion: A Meta-analysis of Individual-Participant Data
Simmonds MC, Brown JV, Heirs MK, Higgins JP, Mannion RJ, Rodgers MA, Stewart LA. Ann Intern Med. 2013;158:877-889.
-
Comparative safety and effectiveness of cognitive enhancers for Alzheimer’s dementia: protocol for a systematic review and individual patient data network meta-analysis
Veroniki AA, Straus SE, Ashoor HM, et al Comparative safety and effectiveness of cognitive enhancers for Alzheimer’s dementia: protocol for a systematic review and individual patient data network meta-analysis BMJ Open 2016;6:e010251. doi: 10.1136/bmjopen-2015-010251